Ticker Details
Brainstorm Cell Therapeutics Inc. Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company develops novel adult stem cell therapies for debilitating neurodegenerative disorders such as ALS, MS, and PD among others.
IPO Date:	November 1, 2003
Sector:	Healthcare
Industry:	Biotech
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.11 | 3.53%
Avg Daily Range (30 D):	$0.04 | 4.80%
Avg Daily Range (90 D):	$0.03 | 5.21%

Institutional Daily Volume
Avg Daily Volume:	.1M
Avg Daily Volume (30 D):	.01M
Avg Daily Volume (90 D):	.02M

Trade Size
Avg Trade Size (Sh.):	75
Avg Trade Size (Sh.) (30 D):	627
Avg Trade Size (Sh.) (90 D):	826

Institutional Trades
Total Institutional Trades:	43
Avg Institutional Trade:	$2.23M
Avg Institutional Trade (30 D):	$.62M
Avg Institutional Trade (90 D):	$.62M
Avg Institutional Trade Volume:	.03M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.72M
Avg Closing Trade (30 D):	$M
Avg Closing Trade (90 D):	$M
Avg Closing Volume:	29.88K

News

Mar 31, 2026 @ 8:01 PM BrainStorm Cell Therapeutics Announces Full Year 2... Source: Prnewswire

Feb 26, 2026 @ 11:22 AM Brainstorm Cell Therapeutics Secures Second $1 Mil... Source: Prnewswire

Feb 20, 2026 @ 11:00 AM Brainstorm Cell Therapeutics Announces $1 Million ... Source: Prnewswire

Aug 14, 2025 @ 11:02 AM BrainStorm Cell Therapeutics Announces Second Quar... Source: Prnewswire

Jul 18, 2025 @ 9:36 AM Brainstorm Cell Therapeutics Crashes 42% After Vol... Source: Mohd Haider

Financials
	TTM	Q1 2025	Q4 2024
Basic EPS	$-.34	$-.45	$-.51
Diluted EPS	$-.34	$-.45	$-.51
Revenue
Gross Profit
Net Income / Loss	$-2.9M	$-2.86M	$-2.97M
Operating Income / Loss	$-2.57M	$-3.09M	$-3.19M
Cost of Revenue
Net Cash Flow	$M	$M	$-1.11M
PE Ratio

Splits
Oct 01, 2024	1:15
Sep 16, 2014	1:15
Aug 13, 2003	2:1